A Phase 2 interventional study of Voriconazole in Pharmacokinetics, sponsored by Pfizer. Completed at 9 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-05-05.
Sponsored by Pfizer · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is designed to collect additional pharmacokinetic and safety data of voriconazole in immunocompromised adolescents receiving intravenous and oral voriconazole. This will help establish voriconazole dosing recommendations for adolescents.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Voriconazole
Voriconazole will be used for prophylaxis purpose. 6 mg/kg IV q12h on the first day (Day 1) and 4 mg/kg IV q12h for at least 5.5 days. The IV treatment is no more than 20 days. Then switch to 300 mg oral tablets q12h for at least 6.5 days. The total treatment duration is no more than 30 days.
Also known as: Vfend
Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time frame: Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion
Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration
Time frame: Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion
Time to Reach Cmax (Tmax) Following IV Administration
Time frame: Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6, 8 and 12 hours after start of infusion
AUC12,ss Following Oral Administration
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose
Cmax,ss Following Oral Administration
Time frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose
Tmax Following Oral Administration
Time frame: Day 7 (up to Day 30) Predose, 1, 2, 4, 6, 8, and 12 hours postdose
AUC12 Following IV Loading Dose
AUC12 = Area under the plasma concentration-time profile from time zero (predose) to twelve hours. AUC12 was obtained by the Linear/Log trapezoidal method.
Time frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion
Tmax Following an IV Loading Dose
Time frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion
Cmax Following an IV Loading Dose
Time frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion
Minimum Observed Plasma Trough Concentration (Cmin)
Time frame: Day 7 (up to Day 20) for IV; Day 7 (up to Day 30) for oral at predose
AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion
Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
Time frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion
Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following IV Administration
Time frame: Day 1 at predose, 60, 118 minutes, 4, 6, 8 and 12 hours after start of infusion and on Day 7 (up to Day 20) at predose, 40, 78 minutes, 4, 6 8 and 12 hours after start of infusion
AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
Time frame: On Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose
Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
Time frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose
Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration
Time frame: Day 7 (up to Day 30) at predose, 1, 2, 4, 6, 8, and 12 hours postdose
Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 IV Loading Dose.
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Time frame: Day 1
Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 IV Steady State
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Time frame: Day 7 of IV dosing
Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 Oral Dose All Subjects
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Time frame: Day 7 Oral dosing
Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - AUC12 Oral 300mg
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Time frame: Day 7 oral dosing
Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax IV Loading Dose
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Time frame: Day 1
Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax IV Steady State
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Time frame: Day 7 of Intravenous dosing
Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax Day 7 Oral All Participants
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Time frame: Day 7 of oral dosing
Pharmacokinetic Parameters of Voriconazole in Adolescents Compared to Historical Adult Data - Cmax 300 mg Oral Dose
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Time frame: Day 7 of oral dosing
| Milestone | All Treatments |
|---|---|
| Started | 26 |
| Treated | 26 |
| Completed | 21 |
| Not completed | 5 |
| Withdrew: Adverse event | 1 |
| Withdrew: Other | 4 |
| Milestone | All Treatments |
|---|---|
| Started | 22 |
| Completed | 20 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Intolerant of oral treatment | 1 |
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
| μg*h/mL | Voriconazole IV |
|---|---|
| Area Under the Curve Over Dosing Interval at Steady State (AUC12,ss) Following IV Administration | 22.39 ± 21.47 |
| μg/mL | Voriconazole IV |
|---|---|
| Peak Plasma Concentration at Steady State (Cmax,ss) Following IV Administration | 3.89 ± 2.59 |
| hours | Voriconazole IV |
|---|---|
| Time to Reach Cmax (Tmax) Following IV Administration | 1.30 (1.17 to 3.95) |
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
| μg*h/mL | Voriconazole Oral |
|---|---|
| AUC12,ss Following Oral Administration | 16.74 ± 13.50 |
| μg/mL | Voriconazole Oral |
|---|---|
| Cmax,ss Following Oral Administration | 2.35 ± 1.41 |
| hours | Voriconazole Oral |
|---|---|
| Tmax Following Oral Administration | 2.00 (0.67 to 8.10) |
AUC12 = Area under the plasma concentration-time profile from time zero (predose) to twelve hours. AUC12 was obtained by the Linear/Log trapezoidal method.
| μg*h/mL | Voriconazole IV |
|---|---|
| AUC12 Following IV Loading Dose | 9.14 ± 4.90 |
| hours | Voriconazole IV |
|---|---|
| Tmax Following an IV Loading Dose | 1.97 (1.90 to 2.08) |
| μg/mL | Voriconazole IV |
|---|---|
| Cmax Following an IV Loading Dose | 2.25 ± 0.86 |
| μg/mL | All Treatments |
|---|---|
| IV Day 7 (up to Day 20) (n=21) | 1.05 ± 1.85 |
| Oral Day 7 (up to Day 30) (n=19) | 0.72 ± 0.81 |
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
| μg*h/mL | Voriconazole IV |
|---|---|
| Day 1 | 21.18 ± 6.80 |
| Day 7 (up to Day 20) | 36.21 ± 9.20 |
| μg/mL | Voriconazole IV |
|---|---|
| Day 1 | 2.50 ± 0.84 |
| Day 7 (up to Day 20) | 3.48 ± 0.73 |
| μg*h/mL | Voriconazole IV |
|---|---|
| Day 1 | 4.00 (1.97 to 8.03) |
| Day 7 (up to Day 20) | 4.03 (0.00 to 12.10) |
AUC12,ss = Area under the plasma concentration-time profile from time zero (predose) to twelve hours at steady-state. AUC12,ss was obtained by the Linear/Log trapezoidal method.
| μg*h/mL | Voriconazole Oral |
|---|---|
| AUC12,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration | 44.07 ± 13.86 |
| μg/mL | Voriconazole Oral |
|---|---|
| Cmax,ss of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration | 4.44 ± 1.43 |
| hours | Voriconazole Oral |
|---|---|
| Tmax of N-oxide Voriconazole Metabolite (UK-121, 265) Following Oral Administration | 5.97 (1.00 to 8.10) |
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Results for this outcome have not been posted.
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Results for this outcome have not been posted.
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Results for this outcome have not been posted.
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Results for this outcome have not been posted.
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Results for this outcome have not been posted.
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Results for this outcome have not been posted.
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Results for this outcome have not been posted.
Data for this Outcome Measure are not reported here because the analysis population includes participants who were not enrolled in this study. ClinicalTrials.gov is designed for reporting results from only those participants who were enrolled in the study and described in the Participant Flow and Baseline Characteristics modules.
Results for this outcome have not been posted.
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Voriconazole IV | — | 4/26 (15.4%) | 26/26 (100%) |
| Voriconazole Oral | — | 4/22 (18.2%) | 22/22 (100%) |
| Event | Voriconazole IV | Voriconazole Oral |
|---|---|---|
| NauseaGastrointestinal disorders | 0/26 | 1/22 |
| VomitingGastrointestinal disorders | 0/26 | 1/22 |
| Acute graft versus host disease in intestineImmune system disorders | 0/26 | 1/22 |
| Acute graft versus host disease in liverImmune system disorders | 0/26 | 1/22 |
| Blood bilirubin increasedInvestigations | 0/26 | 1/22 |
| Decreased appetiteMetabolism and nutrition disorders | 0/26 | 1/22 |
| DepressionPsychiatric disorders | 0/26 | 1/22 |
| Cystitis haemorrhagicRenal and urinary disorders | 0/26 | 1/22 |
| Renal failure acuteRenal and urinary disorders | 1/26 | 1/22 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/26 | 1/22 |
| Event | Voriconazole IV | Voriconazole Oral |
|---|---|---|
| PyrexiaGeneral disorders | 13/26 | 5/22 |
| Mucosal inflammationGeneral disorders | 11/26 | 9/22 |
| NauseaGastrointestinal disorders | 6/26 | 6/22 |
| DysuriaRenal and urinary disorders | 1/26 | 6/22 |
| HypertensionVascular disorders | 4/26 | 6/22 |
| DiarrhoeaGastrointestinal disorders | 5/26 | 5/22 |
| VomitingGastrointestinal disorders | 5/26 | 5/22 |
| Oxygen saturation decreasedInvestigations | 1/26 | 5/22 |
| Fluid retentionMetabolism and nutrition disorders | 4/26 | 5/22 |
| Bone painMusculoskeletal and connective tissue disorders | 2/26 | 5/22 |
| Age, Customized(Years) | All Treatments |
|---|---|
| 12 | 4 |
| 13 | 10 |
| >13 to <17 | 12 |
| Sex/Gender, Customized(Participants) | All Treatments |
|---|---|
| Female | 9 |
| Male | 17 |
The record gives a start of Jun 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2012, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voriconazole